Available Until 8/20/2024

The Level is in the Details: Beta-lactam Therapeutic Drug Monitoring

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 View more SIDPEC Activities

Activity Description

In this episode of Breakpoints: The SIDP Podcast, Erin McCreary moderates an expert panel discussion surrounding the utility of beta-lactam therapeutic drug monitoring (BL-TDM). In a dynamic and wide-ranging conversation, panelists address key concepts such as beta-lactam targets and exposure thresholds, populations that may uniquely benefit from BL-TDM, the relationship between BL-TDM and clinical outcomes, and practical considerations for implementation. Pharmacists who participate in this activity will gain an understanding of fundamental BL-TDM principles along with real-world examples of successful clinical application.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:

  • Determine optimal patient populations for beta-lactam therapeutic drug monitoring.
  • List optimal threshold exposures for beta-lactam therapeutic drug monitoring.
  • Describe how to implement a beta-lactam therapeutic drug monitoring program at your institution.
  • Explain various assays for beta-lactam therapeutic drug monitoring and how to interpret results.


Joseph L. Kuti, PharmD, FIDP
Associate Director, Clinical and Economic Studies
Center for Anti-Infective Research and Development
Hartford HealthCare, Hartford Hospital
Hartford, CT

Veena Venugopalan, PharmD, BCIDP
Clinical Associate Professor
University of Florida, College of Pharmacy
Department of Pharmacotherapy and Translational Research
Gainesville, FL

Marc H. Scheetz, PharmD, MSc, FCCP, BCPS AQ-ID
Professor, Midwestern University
Chicago College of Pharmacy, Department of Pharmacy Practice
College of Graduate Studies, Department of Pharmacology
College of Graduate Studies, Department of Biomedical Sciences
Director, Pharmacometrics Center of Excellence
Infectious Diseases Pharmacist, Northwestern Medicine
Department of Pharmacy
Chicago, IL

Jason Roberts, PhD, B Pharm (Hons), B App Sc, FSHP, FISAC
Professor of Medicine and NHMRC Practitioner Fellow, The University of Queensland
Pharmacist Consultant, Royal Brisbane and Women’s Hospital
Interim Director, Herston Infectious Diseases Institute (HeIDI), Metro North Health
Queensland, Australia

Moderator: Erin K. McCreary, PharmD, BCPS, BCIDP
Antimicrobial Stewardship/Infectious Diseases Clinical Pharmacist
University of Pittsburgh Medical Center
Pittsburgh, PA

CE Accreditation

Release Date: August 20, 2021
Expiration Date: August 20, 2024
BCIDP Expiration Date: August 20, 2022


This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-171-H01-P has been assigned to this home-study, knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.


The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 8/20/2021 for this activity and is available for one year from this date.

Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Joe Kuti has received research funding from Shionogi, Merck & Co., Inc., Summit Pharma, Contrafect, bioMeriuex and Spero, consulting fees from GSK and bioMerieux, and served as a speaker for Abbvie. Erin McCreary has served as a consultant for Abbvie, Entasis, Summit, Merck, Shinogi, Ferring and Cidara and has received other financial support from Infectious Disease Connect. Jason Roberts has received consulting fees from Pfizer, Sandoz, Wolters Kluwer and Cipla. Marc Scheetz reports personal fees from Achaogen, grants from Merck and Co., grants and personal fees from Various non-profits and Universities, grants from Allecra, grants from Nevakar, personal fees from Hall, Booth, Smith, P.C., personal fees from Chambless, Higdon, Richardson, Katz & Griggs, LLP, grants from SuperTrans Medical, personal fees from Abbvie, personal fees from Premier Healthcare Solutions, personal fees from Taylor, English, Duma, LLP, grants from NIH , grants from Cystic Fibrosis Foundation, outside the submitted work; In addition, Dr. Scheetz has a patent US10688195B2 issued. Veena Venugopalan has received research funding from Merck and Melinta.


This activity is provided by ProCE, LLC and SIDP.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.